No Data
No Data
Hong Kong stock market fluctuations | CXO concept stocks continue to rise in early trading. The Biosecurity Law is still waiting for the Senate to vote. Citigroup said that the stock price of the Chinese pharmaceutical company has been undervalued.
CXO concept stocks continued to rise in the morning session. As of the time of writing, Wuxi Bio (02269) rose 4.6% to HK$11.82; Wuxi Apptec (02359) rose 4.51% to HK$35.95; Pharmaron (03759) rose 3.84% to HK$9.73; Asymchem Laboratories (06821) rose 3.84% to HK$41.95.
Jiajiayue Group: In the second quarter of 2024, it plans to repurchase shares worth 0.1 billion yuan to 0.2 billion yuan; Shanghai Guijiu: The actual controller, Han Xiao, has been taken into custody by criminal compulsory measures.
[Company Business Data] Fujian Tianma Science and Technology Group (603668.SH): The cumulative eel output from April to August is approximately 7491.82 tons. Dalian Huarui Heavy Industry Group (002204.SZ): The net income is expected to increase by 20.70% to 27.05% in the first three quarters. Shanxi Lu’an Environmental Energy Dev.Co.,Ltd (601699.SH): The sales volume of commodity coal in August is 4.38 million tons, a year-on-year decrease of 4.16%. China Pacific Insurance (601601.SH): The premium of Pacific Life Insurance in the first 8 months was 191.729 billion yuan, a year-on-year increase of 1.5%. [Signed Projects] Zhejiang Jingxing Paper Joint Stock (002067.SZ): The household paper business department added a new 200
Some directors, senior management, core technical and business personnel of Asymchem Laboratories (06821.HK) are planning to increase their shareholding in the company's A shares.
Grorgon reported on September 11th that Asymchem Laboratories (06821.HK) announced that on September 11, 2024, the company received written notifications from directors Zhang Da, Hong Liang, Zhang Ting, senior executives Jiang Yingwei, Chen Chaoyong, Zhou Yan, Xu Xiangke, and some core technical and business personnel (hereinafter referred to as "shareholding entities"). The above-mentioned shareholding entities, based on their confidence in the company's future sustainable and stable development prospects and their recognition of the company's value, plan to increase their A-shareholding through centralized competitive trading to promote the company's continuous, stable, and healthy development, safeguard the interests of the company's investors, and intend to increase the total shareholding amount.
Some directors, senior management personnel, core technical and business personnel of Asymchem Laboratories (06821) plan to increase their holdings of no less than 20 million yuan of company A shares.
Asymchem Laboratories (06821) announced that Asymchem Pharmaceuticals Tianjin Co., Ltd. (hereinafter referred to as the “company”...
Hong Kong stocks rebounded collectively with the CRO concept stocks, WuXi AppTec announced another 1 billion yuan buyback. The Biosafety Law is still awaiting a vote in the Senate.
CRO concept stocks rebounded collectively. As of the time of writing, Pharmaron (03759) rose by 4.57%, at HKD 9.38; WuXi AppTec (02359) rose by 4.04%, at HKD 33.5; Frontage Holdings (01521) rose by 3.57%, at HKD 0.58.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
No Data
No Data